APLS(Delisted)
Stock Fundamental
Valuation1.7/10
BearishKey Valuation Metric
PE Method: APLS's market cap is approximately 5.25B with TTM earnings of 13.33B, corresponding to a PE ratio of 39.4. Compared to the Pharmaceuticals industry average, this valuation may be reasonable.
PS Method: APLS's market cap is approximately 5.25B with a PS ratio of 4.8. Compared to the Pharmaceuticals industry average, this valuation may be reasonable.
PEG Method: With a PE of 39.4 and forward PE of 39.4, the PEG ratio comes to 1.00, indicating a reasonable valuation.
Historical Price to Earnings Ratio
Historical data shows that APLS's P/E reached a peak of about 154.40 on 2026-01-09, and a trough of about -21.79 on 2025-01-07. The current P/E is 39.41, which places it at approximately the 35% percentile of its historical range, indicating a relatively reasonable valuation.
Share Price vs Future Cash Flow Value
APLS's current stock price is about $41.03, while its Discounted Cash Flow valuation is about $42.74. Based on the Discounted Cash Flow model, the market price represents a price close to its intrinsic value.
Future Growth7.1/10
BullishEarnings and Revenue Growth Forecasts
APLS's Earnings moved from about -37.66M (2024) to about 18.66M (2026) in recent actuals. Analyst forecasts include about 66.81M, 81.01M, and 95.21M for the next forecast periods, implying an overall 3-year CAGR of roughly 72.2% versus the latest actual—indicating an upward trend in Earnings..
Future Return on Equity
Analysts predict APLS's future return on equity (Future ROE) will be about -2.1% over the next three years, higher than the Pharmaceuticals industry average of -66.9%, indicating its leading position in capital profitability. A higher Future ROE generally reflects stronger expected profitability on shareholder equity, subject to business risk and accounting differences.
Past Performance6.4/10
NeutralRevenue & Expenses Breakdown
APLS's revenue primarily comes from Product, Licensing, — and —. Among these, Product accounts for 68.7%; Licensing for 31.3%, — for 0.0% and — for 0.0%. The company's main business is relatively concentrated.
Earnings & Revenue
- Earnings per share (TTM)0.75
- Gross margin84.89%
- Net profit margin6.95%
- Debt / equity1.61x
The company's earnings quality is weaker. Net profit for the latest fiscal period is about 18.66M, while free cash flow is estimated at -21.81M. The 40.46M difference between the two indicates significant cash conversion capabilities. suggesting a meaningful gap between accounting earnings and cash generation, often driven by non-cash items or working capital.
Free Cash Flow vs Earnings Analysis
APLS's net income is about 95.21M, while free cash flow is about -21.81M, representing a FCF/Earnings ratio of -22.9%. The conversion from earnings to free cash flow is weak, indicating significant non-cash items or working capital effects may be pressuring cash conversion.
Financial Health5.5/10
NeutralDebt to Equity History and Analysis
In 2026-03, total liabilities (Debt) are about 667.61M; total equity (Equity) is about 414.92M. These figures come from the financial health diagnose series (debt / equity). They describe capital structure, not operating earnings.
Balance Sheet
Assets
Liabilities + Equity
The company's shareholders' equity is $414.92M, representing about 38.3% of total assets, while total debt is $384.16M, representing about 35.5% of total assets. This low-leverage structure means expansion relies primarily on profits and equity capital, resulting in lower financial risk.
Dividends4.0/10
NeutralStability and Growth of Payments
APLS is not paying a notable dividend in the U.S. market context; detailed stability and growth checks are less relevant until distributions become material.
Dividend Yield vs Market
APLS's current dividend yield is 0.00%, while the Pharmaceuticals industry average is around 3.56%. The top 25% of companies in the entire US market have a dividend yield of 4.56%, while the bottom 25% have a yield of 2.48%. In comparison, APLS is clearly at the bottom of the industry.
Earnings Payout to Shareholders
Earnings coverage: APLS is not paying a notable dividend for the US market.
Cash Payout to Shareholders
Cash flow coverage: APLS is not paying a notable dividend for the US market.
- Based on a composite score of 6.67/10, we rate APLS as a Netural. Our analysis breaks down into 1.97/10 for Fundamentals, 8.19/10 for Technicals, and 7.02/10 for Sentiment, indicating the stock is likely to consolidate sideways.
- Based on a composite score of 6.67/10, we rate APLS as a Netural. Our analysis breaks down into 1.97/10 for Fundamentals, 8.19/10 for Technicals, and 7.02/10 for Sentiment, indicating the stock is likely to consolidate sideways.
